Search Medical Condition
Please enter condition
Please choose location from dropdown

Stralsund, Germany Clinical Trials

A listing of Stralsund, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population.

The main objective of the proposed non-interventional study is to obtain real-world effectiveness, safety and treatment patterns data of patients with BRCAm+ (Breast Cancer Gene(s) mutation positive) platinum sensitive relapsed (PSR) ovarian cancer in German hospitals and outpatient practices treated with olaparib.

Phase N/A

0.0 miles

Learn More »

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

This is an international, multicenter (study conducted at multiple sites) study designed to estimate remission rates and assess treatment response, tolerability, and patterns of use of Paliperidone Palmitate 3-Month Formulation (PP3M) in a diverse population of participants with schizophrenia. The study will consist of a screening phase (Day -7 to ...

Phase

0.0 miles

Learn More »

Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation

Parkinson's disease (also known as Parkinson's, Parkinson disease, or PD) is a degenerative disorder of the central nervous system that impairs motor skills, cognitive processes, and other functions. The most obvious symptoms are motor-related, including tremor, rigidity, slowness of movement, and postural instability. Among non-motor symptoms are autonomic dysfunction and ...

Phase N/A

0.0 miles

Learn More »

Treatment-Resistant Depression Cohort in Europe

This TRD cohort study will collect critically important data from routine clinical practice in Europe which will further substantiate the understanding of TRD in European clinical practice, with the aim of improving guidance and informing the development of better treatment strategies for this medically important condition. All data recorded in ...

Phase N/A

0.87 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

1.51 miles

Learn More »

Praegnant Breast Cancer

Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis. Not only with regard to therapy decisions but also with regard to quality assured healthcare and health economics this entity of patients remains a challenge. Recently, novel advances in ...

Phase N/A

1.51 miles

Learn More »

Therapy Management With Nab-Paclitaxel in Daily Routine

Despite treatment improvements in breast cancer, a large number of patients still progress to the metastatic stage. Metastatic breast cancer patients have an extremely unfavorable prognosis. Not only efficacy, but also quality of life are in the focus when planning a therapy or therapy sequence for metastatic breast cancer patients. ...

Phase N/A

1.51 miles

Learn More »

Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

Breast cancer is the commonest cancer in women worldwide with an estimated 1.4 million new diagnoses in 2008 and 1.6 million cases estimated for 2015. In 2008 breast cancer was responsible for approximately 23% of all new cancer diagnoses in women. It is also the commonest cause of cancer deaths ...

Phase N/A

1.51 miles

Learn More »